Assessment of Prognosis Using Peripheral Blood Circulating Tumor DNA in Patients With Cervical Cancer

This observational study is conducted to assess the value of using peripheral blood ctDNA to detect dynamic changes in HPV and genetic variants in predicting the prognosis of patients with locally advanced cervical cancer, as compared with traditional imaging and tumor markers.

Inclusion Criteria:Patients with initial diagnosis, operable locally advanced cervical cancer, FIGO stage IB2/3-IIA1/2 or initial diagnosis, receive radical chemoradiotherapy locally advanced cervical cancer, FIGO stage IIB-IVANot receiving systemic treatmentPathological diagnosis: cervical squamous cell carcinomaAged 18-70 yearsECOG PS: 0-1Patients volunteer to participate in this study and sign the informed consent, with good compliance, and cooperate with the acquisition of tissue samples and blood samplesExclusion Criteria:Patients diagnosed with other malignancies within 5 yearsPatients had received previous systemic antitumor therapyIn the judgment of the investigator, the patients had other factors that might have caused the study to be discontinued